

Supplementary Material

Table S1. Ingredients, calculated, and analyzed compositions of experimental diets¹ (as-fed basis, percentage (%), unless otherwise stated).

| Ingredients | Phases | | | |
|--|------------------------|-----------------|------------------|-----------------|
| | Starter (0–14 d) | | Grower (15–28 d) | |
| | Control diet | Antibiotic diet | Control diet | Antibiotic diet |
| Ingredient Composition | | | | |
| Corn (ground) | 51.08 | 50.98 | 45.36 | 45.25 |
| Soybean meal-46.5 | 41.44 | 41.45 | 36.31 | 36.33 |
| Wheat | - | - | 10 | 10 |
| Animal/vegetable fat | 2.93 | 2.97 | 4.22 | 4.26 |
| Limestone | 1.80 | 1.80 | 1.65 | 1.65 |
| Dicalcium Phosphate | 1.24 | 1.24 | 1.06 | 1.06 |
| DL Methionine premix ² | 0.59 | 0.59 | 0.53 | 0.53 |
| Vitamin/Mineral Premix ^{3, 4} | 0.50 | 0.50 | 0.50 | 0.50 |
| Salt | 0.41 | 0.41 | 0.37 | 0.37 |
| Lysine HCl | 0.01 | 0.01 | 0.00 | 0.00 |
| BMD 110G ⁵ | - | 0.05 | - | 0.05 |
| Total | 100 | 100 | 100 | 100 |
| Nutrient | Calculated composition | | | |
| Metabolizable energy (kcal/kg) | 3,000 | 3,000 | 3,100 | 3,100 |
| Crude protein | 23 | 23 | 21.5 | 21.5 |
| Calcium | 0.96 | 0.96 | 0.87 | 0.87 |
| Available phosphorus | 0.48 | 0.48 | 0.44 | 0.44 |
| Sodium | 0.19 | 0.19 | 0.18 | 0.18 |
| Digestible lysine | 1.28 | 1.28 | 1.15 | 1.16 |
| Digestible methionine + cysteine | 0.95 | 0.95 | 0.87 | 0.87 |
| Digestible Tryptophan | 0.25 | 0.25 | 0.23 | 0.23 |
| Digestible Threonine | 0.89 | 0.89 | 0.82 | 0.82 |
| Analyzed composition | | | | |
| Dry Matter | 90.7 | 90.8 | 93.2 | 93.5 |
| Crude protein | 24.8 | 25 | 22.5 | 23.8 |
| Crude fat | 5.50 | 5.79 | 6.84 | 6.85 |
| Calcium | 1.06 | 1.13 | 1.00 | 0.96 |
| Potassium | 1.14 | 1.16 | 0.99 | 1.04 |
| Phosphorus | 0.69 | 0.70 | 0.67 | 0.62 |
| Sodium | 0.19 | 0.21 | 0.21 | 0.16 |

¹ Basal diet (NC); antibiotic diet containing NC + 0.05% bacitracin methylene disalicylate (BMD). ² Supplied/kg premix: DL-Methionine, 0.5 kg; wheat middling, 0.5 kg. ³ Starter vitamin-mineral premix contained the following per kg of diet: 9750 IU vitamin A; 2000 IU vitamin D3; 25 IU vitamin E; 2.97 mg vitamin K; 7.6 mg riboflavin; 13.5 mg D1 Ca-pantothenate; 0.012 mg vitamin B12; 29.7 mg niacin; 1.0 mg folic acid, 801 mg choline; 0.3 mg biotin; 4.9 mg pyridoxine; 2.9 mg thiamine; 70.2 mg manganese; 80.0 mg zinc; 25 mg copper; 0.15 mg selenium; 50 mg ethoxyquin; 1543 mg wheat middling's; 500 mg ground limestone. ⁴ Grower and Finisher vitamin-mineral premix contained the following per kg of diet: 9750 IU vitamin A; 2000 IU vitamin D3; 25 IU vitamin E; 2.97 mg vitamin K; 7.6 mg riboflavin; 13.5 mg D1 Ca-pantothenate; 0.012 mg vitamin B12; 29.7 mg niacin; 1.0 mg folic acid, 801 mg choline; 0.3 mg biotin; 4.9 mg pyridoxine; 2.9 mg thiamine; 70.2 mg manganese; 80.0 mg zinc; 25 mg copper; 0.15 mg selenium; 50 mg ethoxyquin; 1543 mg wheat middling's; 500 mg ground limestone. ⁵ Bacitracin methylene disalicylate (providing 55 mg/kg mixed feed); AlphaPharma, Inc., Fort Lee, NJ, USA.

Table S2. Sequencing data quality control metrics for 48 liver samples for 6 treatment groups¹.


| Sample | Raw Reads # | Surviving Reads # | Surviving % | Mapped Reads # | Mapped % |
|--------|-------------|-------------------|-------------|----------------|----------|
| 10D | 128931886 | 128864410 | 99.95 | 123496072 | 95.83 |
| 11F | 123815424 | 123749336 | 99.95 | 117546419 | 94.99 |
| 12E | 100217620 | 100171610 | 99.95 | 95675887 | 95.51 |
| 13A | 91263880 | 91218332 | 99.95 | 87621362 | 96.06 |
| 14E | 102874686 | 102803518 | 99.93 | 98365003 | 95.68 |
| 15F | 89610956 | 89558286 | 99.94 | 85844381 | 95.85 |
| 16B | 103696522 | 103649450 | 99.95 | 99566563 | 96.06 |
| 17D | 102727142 | 102673518 | 99.95 | 97718554 | 95.17 |
| 18C | 102658094 | 102589816 | 99.93 | 97517267 | 95.06 |
| 19E | 114613450 | 114541804 | 99.94 | 109055322 | 95.21 |
| 1B | 111989480 | 111935440 | 99.95 | 107217188 | 95.78 |
| 20B | 105128716 | 105083912 | 99.96 | 101140738 | 96.25 |
| 21D | 86558618 | 86518732 | 99.95 | 82682287 | 95.57 |
| 22A | 86201504 | 86143930 | 99.93 | 82400996 | 95.66 |
| 23F | 97189216 | 97135594 | 99.94 | 92538383 | 95.27 |
| 25F | 129747010 | 129692014 | 99.96 | 124312086 | 95.85 |
| 26D | 98609268 | 98564006 | 99.95 | 94445790 | 95.82 |
| 27A | 103167822 | 103122160 | 99.96 | 98995073 | 96.00 |
| 28E | 119433662 | 119384804 | 99.96 | 113827077 | 95.34 |
| 29C | 71048832 | 71015376 | 99.95 | 67880932 | 95.59 |
| 2E | 122294110 | 122221882 | 99.94 | 116442856 | 95.27 |
| 30B | 100435658 | 100385796 | 99.95 | 96299990 | 95.93 |
| 31D | 110590420 | 110541296 | 99.96 | 106048032 | 95.94 |
| 32C | 157571810 | 157485346 | 99.95 | 150219923 | 95.39 |
| 33A | 103717506 | 103676040 | 99.96 | 99480220 | 95.95 |
| 34E | 114963742 | 114911374 | 99.95 | 109633108 | 95.41 |
| 35F | 99621346 | 99571764 | 99.95 | 94015694 | 94.42 |
| 36B | 89037488 | 88999280 | 99.96 | 85651443 | 96.24 |
| 37E | 93691904 | 93644694 | 99.95 | 89307326 | 95.37 |
| 38A | 74565050 | 74529310 | 99.95 | 71237815 | 95.58 |
| 39F | 96777946 | 96716112 | 99.94 | 92174462 | 95.30 |
| 3D | 115361710 | 115292412 | 99.94 | 110464518 | 95.81 |
| 40D | 81332670 | 81290328 | 99.95 | 77473448 | 95.30 |
| 41B | 78153658 | 78115760 | 99.95 | 74718506 | 95.65 |
| 42C | 89136784 | 89093766 | 99.95 | 85224056 | 95.66 |
| 43B | 84600692 | 84556594 | 99.95 | 80853617 | 95.62 |
| 44E | 106835414 | 106789686 | 99.96 | 102394089 | 95.88 |
| 45A | 95541636 | 95493314 | 99.95 | 91460060 | 95.78 |
| 46F | 76636156 | 76598132 | 99.95 | 73012433 | 95.32 |
| 47C | 112641994 | 112573638 | 99.94 | 107374095 | 95.38 |
| 48D | 94773314 | 94702008 | 99.92 | 90015678 | 95.05 |
| 4A | 93142656 | 93092202 | 99.95 | 88266669 | 94.82 |
| 5C | 102491666 | 102433822 | 99.94 | 97796357 | 95.47 |
| 6F | 98781198 | 98720274 | 99.94 | 94109603 | 95.33 |
| 7B | 834450506 | 833996014 | 99.95 | 798312414 | 95.72 |
| 8A | 851554080 | 851180034 | 99.96 | 812162674 | 95.42 |
| 9C | 123838248 | 123780280 | 99.95 | 118300543 | 95.57 |
| 24C | 88404200 | 88369454 | 99.96 | 84734829 | 95.89 |

¹ Treatments include- A) Negative Control treatment- chicks fed a basal corn-soybean meal-wheat-based diet; B) In-feed antibiotics- chicks fed NC + 0.05% bacitracin methylene disalicylate and C) In-water essential oil- chicks supplied the essential oil via the water route at the recommended dosage of 250 mL/1000 L of drinking water; (D) In ovo saline treatment- eggs injected with 0.2 mL of physiological saline (0.9% NaCl); (E) *In ovo* essential oil treatment- eggs injected with 0.2mL of a saline + essential oil blend mixture at a dilution ratio of 2:1, F) *In ovo* + in-water essential oil treatment- chicks offered the essential oil blend via the *in ovo* and in water route, successively.


Table S3. Differentially expressed genes in the liver of broiler chickens as influenced by sex and treatment groups¹.

| Sex Treatments | Gene Symbol | Gene Description | Expression level | log2Fold- Change | P Value | GO Terms | KEGG Pathways |
|---------------------------|----------------|-----------------------------------|---------------------|---------------------|---------|---|--|
| Males (n=28) | | | | | | | |
| B vs. A | INTS2 | integrator complex subunit 2 | Up | 0.5 | <0.01 | snRNA 3'-end processing, | Genetic information processing (Spliceosome) |
| | SLC5A10 | solute carrier family 5-member 10 | Up | 0.7 | 0.01 | glucose transmembrane transport | Signaling and cellular processes (Sodium glucose cotransporter) |
| | MED13 | mediator complex subunit 13 | Up | 0.6 | 0.01 | mediator complex | Transcription machinery (RNA polymerase II system) |
| | CEP70 | centrosomal protein 70 | Up | 0.4 | 0.01 | gamma-tubulin binding | Chromosome and associated proteins |
| | BVES | blood vessel epicardial substance | Down | -0.5 | 0.01 | regulation of microtubule cytoskeleton organization | Tight junction |
| | PDE11A | phosphodiesterase 11A | Down | -0.5 | 0.02 | 3',5'-cyclic-nucleotide phosphodiesterase activity | Phosphoric-diester hydrolases |
| | CLCA1 | chloride channel accessory 1 | Down | -0.5 | <0.01 | intracellular calcium activated chloride channel activity | Signaling and cellular processes (Ion channels) |
| C vs. A | BVES | blood vessel epicardial substance | Down | -0.6 | 0.01 | regulation of microtubule cytoskeleton organization | Tight junction |
| E vs. A | BVES | blood vessel epicardial substance | Down | -0.6 | <0.01 | regulation of microtubule cytoskeleton organization | Tight junction |
| Females (n=20) | | | | | | | |
| B vs. A | PANX2 | pannexin 2 | Up | 1.1 | <0.01 | plasma membrane | signaling and cellular processes (Pores ion channels) |
| C vs. A | GUCY2C | guanylate cyclase 2C | Up | 1.1 | 0.02 | peptide hormone binding | Purine metabolism |
| | MC5R | melanocortin 5 receptor | Down | -0.9 | 0.02 | melanocortin receptor activity | Neuroactive ligand-receptor interaction (Signalling molecules and interaction) |
| F vs. A | MTMR6 | myotubularin related protein 6 | Down | -0.6 | 0.02 | peptidyl-tyrosine dephosphorylation | Phosphatidylinositol signaling system (Inositol phosphate metabolism) |

¹Treatments include- A) Negative Control treatment- chicks fed a basal corn-soybean meal-wheat-based diet; B) In-feed antibiotics- chicks fed NC + 0.05% bacitracin methylene disalicylate and C) In-water essential oil- chicks supplied the essential oil via the water route at the recommended dosage of 250 mL/1000 L of drinking water; D) *In ovo* saline treatment- eggs injected with 0.2 mL of physiological saline (0.9% NaCl); E) *In ovo* essential oil treatment- eggs injected with 0.2mL of a saline + essential oil blend mixture at a dilution ratio of 2:1, F) *In ovo* + in-water essential oil treatment- chicks offered the essential oil blend via the *in ovo* and in water route, successively. Each comparison is specified in the format “B vs. A”, where group B is compared to group A, with group A being the denominator for the comparison. Liver tissues (50–100 mg) was sampled from 8 replicate birds/treatment (independent of sex) using 1 mL TRIzol™ (Qiagen, Hilden, Germany).




(a)




(b)

Figure S1. Rarefaction curves of observed features obtained from 16S rRNA gene V4–V5 sequences on the basis of (a) microbiota source- cecum and ileum and (b) treatment- A) chicks fed a basal corn-soybean meal-wheat-based diet (Negative Control treatment; NC); B) chicks fed NC + 0.05% bacitracin methylene disalicylate (in-feed antibiotics); C) chicks supplied the same commercial blend of EOs via the water route (in-water essential oil) at the recommended dosage of 250 mL/1000 L of drinking water; D) *in ovo* saline treatment; E) *in ovo* essential oil treatment; and F) chicks supplied EO via the *in ovo* and water route (*in ovo* + in-water essential oil treatment)



(a)



(b)

Figure S2. Rarefaction curves of Shannon's index obtained from 16S rRNA gene V4–V5 sequences on the basis of (a) Microbiota source- cecum and ileum and (b) Treatments, which include- A) Negative Control treatment- chicks fed a basal corn-soybean meal-wheat-based diet; B) In-feed antibiotics- chicks fed NC + 0.05% bacitracin methylene disalicylate and C) In-water essential oil- chicks supplied the essential oil via the water route at the recommended dosage of 250 mL/1000 L of drinking water; D) *In ovo* saline treatment- eggs injected with 0.2 mL of physiological saline (0.9% NaCl); E) *In ovo* essential oil treatment- eggs injected with 0.2mL of a saline + essential oil blend mixture at a dilution ratio of 2:1; F) *In ovo* + in-water essential oil treatment- chicks offered the essential oil blend via the *in ovo* and in water route, successively.




Figure S3. PCoA plots based on unweighted UniFrac metric. Each color represents a different comparison of interest. Ileum samples clustered to the left and ceca samples clustered to the right. Treatments include- A) Red: Negative Control treatment- chicks fed a basal corn-soybean meal-wheat-based diet; B) Blue: In-feed antibiotics- chicks fed NC + 0.05% bacitracin methylene disalicylate and C) Pink: In-water essential oil- chicks supplied the essential oil via the water route at the recommended dosage of 250 mL/1000 L of drinking water; D) Green: *In ovo* saline treatment- eggs injected with 0.2 mL of physiological saline (0.9% NaCl); E) Purple: *In ovo* essential oil treatment- eggs injected with 0.2mL of a saline + essential oil blend mixture at a dilution ratio of 2:1, F) Yellow: *In ovo* + in-water essential oil treatment- chicks offered the essential oil blend via the *in ovo* and in water route, successively.




Figure S4. Heatmaps of the top 100 most variable genes. Orange = low expression, blue = high expression. Treatments include- A) Negative Control treatment- chicks fed a basal corn-soybean meal-wheat-based diet; B) In-feed antibiotics- chicks fed NC + 0.05% bacitracin methylene disalicylate and C) In-water essential oil- chicks supplied the essential oil via the water route at the recommended dosage of 250 mL/1000 L of drinking water; D) *In ovo* saline treatment- eggs injected with 0.2 mL of physiological saline (0.9% NaCl); E) *In ovo* essential oil treatment- eggs injected with 0.2mL of a saline + essential oil blend mixture at a dilution ratio of 2:1; F) *In ovo* + in-water essential oil treatment- chicks offered the essential oil blend via the *in ovo* and in water route, successively.




Figure S5. Principal component analysis (PCA) was performed with R package gmodels. The more similar the treatment, the closer the distance reflected in PCA. Treatments include- A) Negative Control treatment- chicks fed a basal corn-soybean meal-wheat-based diet; B) In-feed antibiotics- chicks fed NC + 0.05% bacitracin methylene disalicylate and C) In-water essential oil- chicks supplied the essential oil via the water route at the recommended dosage of 250 mL/1000 L of drinking water; D) *In ovo* saline treatment- eggs injected with 0.2 mL of physiological saline (0.9% NaCl); E) *In ovo* essential oil treatment- eggs injected with 0.2mL of a saline + essential oil blend mixture at a dilution ratio of 2:1, F) *In ovo* + in-water essential oil treatment- chicks offered the essential oil blend via the *in ovo* and in water route, successively.






Figure S6. Gene expression of chrW gene shows much higher expression in Group2 than Group1, indicating that Group2 samples are probably females (n=20) and Group1 samples are probably males (n=28). Group2 are samples with PC1 score > 0, Group 1 are samples with PC1 scores < 0.



(a)



(b)

Figure S7. Gene ontology (GO) classifications of differentially expressed genes (DEGs) between treatment groups in (a) male and (b) female transcripts, respectively. Treatments groups include- A) Negative Control treatment- chicks fed a basal corn-soybean meal-wheat-based diet; B) In-feed antibiotics- chicks fed NC + 0.05% bacitracin methylene disalicylate and C) In-water essential oil- chicks supplied the essential oil via the water route at the recommended dosage of 250 mL/1000 L of drinking water; D) *In ovo* saline treatment- eggs injected with 0.2 mL of physiological saline (0.9%

NaCl); E) *In ovo* essential oil treatment- eggs injected with 0.2mL of a saline + essential oil blend mixture at a dilution ratio of 2:1, F) *In ovo* + in-water essential oil treatment- chicks offered the essential oil blend via the *in ovo* and in water route, successively. Gene Ontology terms included both biological process (BP), cellular component (CC), and molecular function (M).